PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status-Reference-Cited by-同舟云学术

PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status

Published:2018-01 Issue: Volume:8 Page:12-16
ISSN:2405-6308
Container-title:Clinical and Translational Radiation Oncology
language:en
Short-container-title:Clinical and Translational Radiation Oncology

Author:

Fulton Ben,Short Susan C.,James Allan,Nowicki Stefan,McBain Catherine^ORCID,Jefferies Sarah,Kelly Caroline,Stobo Jon^ORCID,Morris Anna,Williamson Aoife,Chalmers Anthony J.

Funder

AstraZeneca

Cancer Research UK

Brain Tumour Charity

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology

Reference21 articles.

1. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012;Ferlay;Eur J Cancer,2013

2. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma;Stupp;N Engl J Med,2005

3. MGMT gene silencing and benefit from temozolomide in glioblastoma;Hegi;N Engl J Med,2005